Niklas Andersson

Niklas Andersson

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
JAJosep M. Anto
Josep M. Anto
Jean BousquetJean Bousquet
Jean Bousquet
MAMubeccel Akdis
Mubeccel Akdis
CACharles Auffray
Charles Auffray
TKThomas Keil
Thomas Keil
CXCheng-Jian Xu
Cheng-Jian Xu

1 October 2019 in Environmental Health Perspectives
Verified
Journal Article
Open access
PLPetter Ljungman
Petter Ljungman
NANiklas Andersson
Niklas Andersson
LSLeo Stockfelt
Leo Stockfelt
EAEva M. Andersson
Eva M. Andersson
JSJohan Nilsson Sommar
Johan Nilsson Sommar
GPGöran Pershagen
Göran Pershagen
Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.

1 March 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AAAnna Asarnoj
Anna Asarnoj
CHCarl Hamsten
Carl Hamsten
KWKonrad Wadén
Konrad Wadén
CLChristian Lupinek
Christian Lupinek
NANiklas Andersson
Niklas Andersson
MHMarianne van Hage
Marianne van Hage

1 May 2015 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MWMarit Westman
Marit Westman
CLChristian Lupinek
Christian Lupinek
JBJean Bousquet
Jean Bousquet
NANiklas Andersson
Niklas Andersson
SPSandra Pahr
Sandra Pahr
MWMagnus Wickman
Magnus Wickman

24 April 2015 in Allergy
Verified
Journal Article
Open access
PDF file
Jean BousquetJean Bousquet
Jean Bousquet
JAJ. M. Anto
J. M. Anto
MWM. Wickman
M. Wickman
TKT. Keil
T. Keil
RVR. Valenta
R. Valenta
LHL. von Hertzen
L. von Hertzen
Allergic diseases [asthma, rhinitis and atopic dermatitis (AD)] are complex. They are associated with allergen‐specific IgE and nonallergic mechanisms that may coexist in the same patient. In addition, these diseases tend to cluster and patients present concomitant or consecutive diseases (multimorbidity). IgE sensitization should be considered as a quantitative trait. Important clinical and immunological differences exist between mono‐ and polysensitized subjects. Multimorbidities of allergic diseases share common causal mechanisms that are only partly IgE‐mediated. Persistence of allergic diseases over time is associated with multimorbidity and/or IgE polysensitization. The importance of the family history of allergy may decrease with age. This review puts forward the hypothesis that allergic multimorbidities and IgE polysensitization are associated and related to the persistence or re‐occurrence of foetal type 2 signalling. Asthma, rhinitis and AD are manifestations of a common systemic immune imbalance (mesodermal origin) with specific patterns of remodelling (ectodermal or endodermal origin). This study proposes a new classification of IgE‐mediated allergic diseases that allows the definition of novel phenotypes to (i) better understand genetic and epigenetic mechanisms, (ii) better stratify allergic preschool children for prognosis and (iii) propose novel strategies of treatment and prevention.

1 December 2017 in EBioMedicine
Verified
Journal Article
Open access
MWMagnus Wickman
Magnus Wickman
CLChristian Lupinek
Christian Lupinek
NANiklas Andersson
Niklas Andersson
DBDanielle Belgrave
Danielle Belgrave
AAAnna Asarnoj
Anna Asarnoj
MHMarianne van Hage
Marianne van Hage
Sensitization in early childhood may precede respiratory allergy in adolescence. IgE reactivity against 132 allergen molecules was evaluated using the MeDALL microarray in sera obtained from a random sample of 786 children at the age of 4, 8 and 16years in a population based birth cohort (BAMSE). Symptoms were analyzed by questionnaire at ages 4, 8 and 16years. Clinically and independent relevant allergen molecules accounting for ≥90% of IgE reactivities in sensitized individuals and at all time-points were identified as risk molecules and used to predict respiratory allergy. The data was replicated in the Manchester Asthma and Allergy Study (MAAS) birth cohort by studying IgE reactivity with the use of a commercial IgE microarray. Sera were obtained from children at the ages of 3, 5, 8 and 11years (N=248) and the outcome was studied at 11years. In the BAMSE cohort 4 risk molecules could be identified, i.e.: Ara h 1 (peanut), Bet v 1 (birch), Fel d 1 (cat), Phl p 1 (grass). For MAAS the corresponding number of molecules was 5: Der p 1 (dust mite), Der f 2 (dust mite), Phl p 1 (grass), Phl p 5 (grass), Fel d 1 (cat). In BAMSE, early IgE reactivity to ≥3 of 4 allergen molecules at four years predicted incident and persistent asthma and/or rhinitis at 16years (87% and 95%, respectively). The corresponding proportions in the MAAS cohort at 16years were 100% and 100%, respectively, for IgE reactivity to ≥3 of 5 risk molecules. IgE reactivity to a few allergen molecules early in life identifies children with a high risk of asthma and/or rhinitis at 16years. These findings will be of importance for developing preventive strategies for asthma and rhinitis in children.